\
&
Contact us
This was 1 year ago
LocationSeville, Spain and online
ProgrammesAndalucia TRADE is hosting the International Forum on Dual-Use Technologies. This annual forum has contributed to fostering a dynamic ecosystem around dual-use technologies—those with both civilian and military applications—by bringing together SMEs, large corporations, research organizations, and universities to explore collaborative opportunities.
The 2024 edition focuses on the space industry, reflecting Seville's growing role in this sector. The city proudly hosts key organizations and initiatives related to space and innovation, highlighting its strategic importance in fostering industrial and technological development.
This forum is open to participants from research centres, SMEs, universities, large industries, incubators, start-ups, innovators, policymakers, institutions, investors, associations, and all professionals engaged in the space and defence sectors.
On Day 1 (29th October)
On Day 2 and Day 3 (30th, 31st October)
More information in B2B Meetings and on the website: https://dualuse2024.b2match.io/page-121
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.